Parkinson’s Patients Can Speak With ‘Intent’ at Hackensack Meridian
Two clinically-proven speech therapy programs tailored to Parkinson’s disease patients, SPEAK OUT! and The LOUD Crowd, are now available at the…
Articles by Patricia Inácio, PhD
Risk of Developing Dementia Higher in Parkinson’s: Follow-up Study
The risk of developing dementia appears to be higher among people with Parkinson’s disease when compared to age and…
FDA Seeking Information Before OK of Apomorphine Infusion Device
The U.S. Food and Drug Administration (FDA) wants more information before it will approve Supernus Pharmaceuticals’ new drug application…
Innervace Raises $40M in Funding for Novel Parkinson’s Cell Therapy
Biotech company Innervace — a spinoff from the University of Pennsylvania — has raised up to $40 million to support…
Tau Protein Buildup in Nerve Cells Prompts Neurodegeneration
A protein “traffic jam” inside nerve cells promotes the buildup of shorter and toxic tau — a protein that forms…
MJFF Grants $500K to Help Develop Alpha-synuclein Imaging Agent
AC Immune will use a new $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to…
Phase 2 Trial Tests DopaFuse for Continuous Oral Levodopa Delivery
SynAgile announced the completion of a Phase 2 clinical trial evaluating DopaFuse, its noninvasive system for the continuous oral delivery…
Amneal Seeks Approval of IPX-203 in US to Boost Patient ‘Good On’ Time
Amneal Pharmaceuticals is seeking U.S. approval of IPX-203, its extended-release carbidopa-levodopa (CD/LD) tablets, for Parkinson’s disease. The company…
Potential of Vaccines in Treating Parkinson’s, Alzheimer’s Detailed
In a webinar hosted by AC Immune, scientists discussed the various advantages of vaccines — ranging from their…
Oxford Parkinson’s Center Partners to Spot Key Progression Biomarkers
The University of Oxford Parkinson’s Disease Centre is working with Metabolon to identify metabolic biomarkers of Parkinson’s risk…